Wednesday, 29 September 2021

Iris Publishers_World Journal of Gynecology & Womens Health (WJGWH)

A Case Report of Severe Intrahepatic Cholestasis of Pregnancy with Severe Liver Damage as the Main Manifestation

Introduction

Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder during pregnancy [1]. Among these patients, bile cannot flow from the liver. The frequency of ICP varies widely between 0.1% and 25% with the specificity of ethnicity and geographic location. More cases about 0.8-1.46% were discovered in South Asian. The greatest prevalence was discovered in South American populations with up to 25% in women of Araucanian Indian. In China, the incidence has been reported be 0.8%-12%. ICP often appears in the late second or third trimester of pregnancy. It is a reversible form of cholestasis and tends to dissolve quickly after birth. Its characters involve pruritus, elevated serum bile acid levels, and abnormal liver function. It has been associated with sudden fetal death and fetal distress, stillbirth, and respiratory distress syndrome of newborn [1].

The diagnosis of ICP involves a rise in serum bile acids and transaminases. in ICP, the liver transaminases aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are commonly elevated, and the elevation may precede the increase in bile acids by 1 to 2 weeks. ALT is more sensitive than AST and may increase 2- to 10-fold in most cases. The primary treatment used for ICP is Ursodeoxycholic acid [2]. Itching often resolve within 48 hours and biochemical abnormalities often recover within 2–8 weeks in most cases [1]. We report here a case with severe liver damage as the main clinical manifestation. The liver function was unexpectedly severely damaged and progressively worsened after delivery, which has puzzled us from diagnosis to treatment.

Case Presentation

Our patient was 36-year woman who first presented to the clinic with a history of two gravidas and one early spontaneous abortion. The gestational age was 38 weeks and 2 days, which was from reliable last normal menstrual period. She receipted regular antenatal care follow up at West China Second University Hospital. She presented to prenatal care clinic with a chief compliant of mild whole-body skin itching, especially around the belly button for one day. She denied history of nausea, vomiting, or abdominal pain and urinary symptoms. She was diagnosed as gestational diabetes mellitus (GDM) in 24 weeks of gestation. Necessary dietary and exercise recommendations were given accordingly. The patient’s blood glucose stayed within the required range since. The patient had a history of hypothyroidism for more than 4 years and had been taking orally 50ug Euthyrox (Levothyroxine Sodium Tablets) per day. Additionally, she had been taking multivitamins (containing 800ug of folic acid) and calcium from the beginning of pregnancy. She had no history of hypertension or hepatitis and constitutional hyperbilirubinemia. Her routine biochemical test one month ago was normal. Physical examination did not reveal abnormal skin and conjunctiva with jaundice. Nausea, vomiting, headache, abdominal pain or fatigue were absent. Blood pressure and vital signs were normal.

Laboratory tests revealed that the direct bilirubin (D-Bil 6.6umol/ml), AST (467 IU/l), ALT (1032 IU/l), and lactate dehydrogenase (LDH, 241 IU/l) were all elevated. Total bile acid level was slightly elevated (15.6 μmol/l) at the time of admission (Table 1). No hemolysis or thrombocytopenia was noted. Viral markers tests of hepatitis A, B, and C were negative. Tests of autoimmune markers including anti-nuclear, anti-mitochondrial, and anti-phospholipid antibodies were negative. The result of Thyroid function was normal. On the basis of these results, she was diagnosed as pregnancy with severe liver function impairment. However, the cause of the severe liver damage was unclear.

Considering that her gestational age was beyond 38 weeks, and that her liver was severely damaged. We decided to perform cesarean section after consultation with the patient and her family. The operation was performed smoothly. The amniotic fluid was clear and slightly yellowish green. The newborn was male, with a birth weight of 2900g and an Apgar score of 10-10-10.

After surgery, the mother had stable vital signs, without anorexia grease or nausea. Her skin and conjunctiva color were normal. The examination on the first day after delivery showed that the liver damage was still severe (Table 1). Kidney function tests were normal. Urine analysis revealed normal color, a pH of 0.5, all negative urine protein, urine biliary element, and bilirubin. The coagulation function test was normal. The symptoms of itchy skin gradually disappeared. After one week of treatment, her liver function deterioration progressively. The patient was transferred to the department of gastroenterology. She was given polyene phosphatidylcholine 930 mg intravenously every day, and 200 mg magnesium isoglycyrrhizinate injection every 12 hours. She underwent further examination. The tests of AMA (antimitochondrial M2 antibody), LKM (anti-liver and kidney particle antibody), LC-1 (anti-hepatic cytosolic antibody), SLA (anti-soluble hepatogen antibody) were negative. The screen of EB virus DNA, hepatitis markers (hepatitis A, B, and C), and TORCH were all negative. The reports of autoimmune antibodies (ELISA) were negative, that included Nrnp/Sm, Smith, SS-A(Ro), SS-B(La), Scl-70, Jo-1, Ro-52, CENPB, PCNA, PM-Scl, NU, MA, HI, dsDNA, RIB, ANA. Tests of immunoglobulin G (IgG), IgA, and IgM were all negative. Complement level were increased, as following: C3 1.74g/L, C4 0.27g/L, IgE 81.10IU/ml.

Her liver fiber ultrasound showed that SWE liver stiffness value was 4.6kpa. Her liver biopsy showed that the liver cells underwent watery degeneration, where there were hepatocyte regeneration and scattered spot necrosis in the liver lobules; some liver cells were cholestatic. Immunohistochemistry showed that HBs-Ag and HBc-Ag were negative, IgG4 was negative, a small number of CD38 were found. The copper and iron staining, PAS and D-PAS of liver cells were all normal (Figure 1). The result was that the patient had mild chronic liver inflammation (G1S1), combined with lymphocyte and plasma cell infiltration (+1), and bile duct changes (-3), so the patient might be suffering from drug-induced liver injury (D1L1), or autoimmune hepatitis (AIH). In addition, based on the patient’s medical history, the pathologist wondered that she might have suffered from intrahepatic cholestasis during pregnancy.

Discussion

Common causes of abnormal liver function during pregnancy include hyperemesis gravidarum, ICP, hypertension in pregnancy, acute fatty liver of pregnancy, autoimmune diseases, viruses, and drug-induced liver toxicity [3]. In this case, the history and clinical evidence of hyperemesis gravidarum and gestational hypertension were lacking. The patient’s autoimmune antibody and virus tests were all negative. Therefore, it is unlikely that the patient’s abnormal liver function was due to autoimmune process or viral infection. About a half of patients suffering drug-induced liver damage may develop cholestasis. Yonghong Zhang, et al. [4] analyzed 9.5 million FDA drug adverse reactions, looking for drugs that may cause cholestasis. They found that an increased risk of cholestasis was associated with lansoprazole, omeprazole, and amoxicillin. The oral medications for this patient during pregnancy were vitamins, calcium and Euthyrox. These drugs have little effect on liver function, and there is no report on these drugs causing severe damage of liver function.

Acute fatty liver of pregnancy (AFLP) is a unique disease in the third trimester. It is a common cause of vesicular fatty infiltration of liver cells and liver failure. The incidence rate is 1/7,000 to 1/15,000. It often occurs at 28-40 weeks of pregnancy. In the biochemical examination of acute fatty liver of pregnancy, serum transaminase, serum uric acid and bilirubin are elevated, and blood clotting time is prolonged. Other typically associated abnormalities include leukocytosis, anemia, hypoproteinemia, thrombocytopenia, coagulation dysfunction, and renal dysfunction. Obviously, except for the elevated level of AST and ALT, her renal function and blood coagulation were normal. There was not sufficient evidence for the diagnosis of AFLP for this patient. Based on all the patient’s test results and her outcome, we wondered that her diagnosis of ICP was the most appropriate.

Internationally, the uniformed diagnostic criteria for ICP have been lack. Most guidelines approve the demands of pruritis and abnormal liver function. The diagnosis of ICP is mainly based on the clinical symptoms. Common laboratory indicators include elevated bilirubin levels, generally not exceeding 6 mg/dL, and transaminase levels rising from the lowest level to 20 times the normal value. The most sensitive laboratory indicator is serum bile acid, and it is the only laboratory abnormality that can be used as a diagnostic criterion. In general, patients with ICP have bile acid> 10 μmol/L, which can be as high as 100 times the normal value, and usually returns to normal 2-8 weeks after delivery.

The etiology of ICP involves many factors including hormonal balance, genetic components and environmental factors. The variation in genetics leads to the different prevalence rates in different ethnic groups [5]. However, to date, the pathogenesis of ICP is still not clear. In recent years, it has been increasingly recognized that the occurrence of ICP is related to metabolic abnormalities, including glucose intolerance and dyslipidemia [6]. A study reported that 19% of ICP patients had GDM, and 13.6% of GDM patients had ICP [7]. Follow-up studies confirmed this result, and the association was stronger. This patient was associated with gestational diabetes and was a high-risk group for ICP.

The clinical condition of ICP patients is generally mild, and most patients only have low-to-moderate abnormalities of liver function. In addition to severe itching, most patients generally do not have serious or long-term complications. In some patients with ICP, transaminase was increased before TBA was increased. ALT and AST were slightly elevated in more than 60% of the patients, generally twice to ten times the normal ranges [8]. In this case, the patient had extremely severe liver failure, and her transaminase was more than 30 times higher than normal ranges, which was extremely rare. One other aspect of the patient’s situation that confused us was that her total bile acid was only slightly elevated, which did not seem to match the high transaminase level. Therefore, it was difficult to reach the diagnosis of ICP when she was first admitted. We had been looking for evidence of such severe liver damage, but no other evidence had been found. 7 days after delivery, the patient’s transaminase did not improve. However, in most cases, the liver function and itching symptoms of ICP patients can be relieved quickly after delivery. Because of the patient’s extremely elevated ALT and AST, she got a liver biopsy to further clarify the cause of liver damage. Normally, patients with ICP do not need liver biopsy. It should only be performed if pruritus-free jaundice occurs before 20 weeks of pregnancy and abnormal laboratory test results continue to occur after 8 weeks of delivery. Even if a liver biopsy is performed in patients with ICP, the liver biopsy will indicate cholestasis with minimal or no inflammatory changes. Her pathological result of liver biopsy was suspected to be diagnosed as ICP. According to all the results, we had to continue to treat her with the ICP treatment principles. Fortunately, after one more week, the patient’s liver function gradually returned to normal.

Conclusion

ICP is a relatively popular hepatic disorder in pregnancy. The prominent contradiction in this case we reported was the rare elevated transaminase, which was also the reason for the difficult diagnosis. The second important point was that the patient’s condition did not relieve but worsened one week after delivery, which was very different from the condition of most ICP patients. The particularity of the onset and outcome of this case, compared with the conventional ICP case, which gives us a new perspective on ICP.

For More Open Access Journals in Iris Publishers Please Click on: https://irispublishers.com/

For More Information:
https://irispublishers.com/wjgwh/fulltext/a-case-report-of-severe-intrahepatic-cholestasis-of-pregnancy-with-severe-liver-damagel.ID.000603.php 


Monday, 13 September 2021

Iris Publishers_World Journal of Gynecology & Womens Health (WJGWH)

An Overview of the Basic Knowledge of Levonorgestrel-Releasing Intrauterine System

Summary

Levonorgestrel-releasing Intrauterine system (LNG-IUS, Mirena) is a very safe, efficient, long-acting and reversible intrauterine device, which releases high-efficiency at a daily dose of 20ug Progesterone mainly acts on the part of the endometrium, causing the endometrial glands to shrink. A large number of studies have fully proved that LNG-IUS is not only effective in contraception, but also widely used in non-contraceptive fields. LNG-IUS is effective in treating gynecological diseases such as menorrhagia and dysmenorrhea. In addition, LNG-IUS is also used in endometriosis, adenomyosis, endometrial polyps, endometrial hyperplasia, and early endometrial cancer. Reversal of cancer and endometrial protection in breast cancer patients. This article will briefly summarize the basic knowledge of LNG-IUS and the clinical application of LNG-IUS in gynecological diseases.

Keywords: Levonorgestrel-releasing Intrauterine system; Mirena; High-efficiency progesterone; Long-acting reversible contraception


Introduction

Levonorgestrel-releasing Intrauterine system (LNG-IUS),its trade name is Mirena. It was originally designed in the 1970s, when the main purpose was to provide safe, efficient, long-acting and reversible contraception (LARC) for women of childbearing age [1]. LNG-IUS is a T-shaped device with a white cylindrical drug core rack on the longitudinal arm, which contains 52mg of levonorgestrel (LNG). The independently designed slow-release system releases 20ug of LNG into the uterine cavity every day. The validity period is 5 years [2]. Currently in China, the approved clinical indications for LNG-IUS mainly include contraception and idiopathic menorrhagia. However, with the continuous deepening of research in recent years, the clinical application of LNG-IUS has become increasingly widespread, and it has already surpassed the scope of approved clinical indications [3]. Based on this, this article will mainly introduce the basic knowledge about LNG-IUS, and briefly summarize the clinical application scope of LNG-IUS and the common confusions and countermeasures of using LNG-IUS.

An Overview of the Basic Knowledge of Levonorgestrel- Releasing Intrauterine System

Levonorgestrel-releasing Intrauterine system (LNG-IUS, Mirena) releases a low blood concentration of levonorgestrel. The blood concentration is reported to be 0.1-0.2ng/ml in the literature [1]. Some key points of knowledge of the Levonorgestrel-releasing Intrauterine system are briefly summarized: ①Levonorgestrelreleasing Intrauterine system contains 52mg of levonorgestrel and releases 20ug of levonorgestrel every 24 hours, the validity period is 5 years [2]. ②What is levonorgestrel (levonorgestrel, LNG)? LNG is a fully synthetic high-efficiency progesterone (sterane synthetic progesterone preparation) It is the optically active form of racemic norgestrel. The progestin activity is twice as strong as norgestrel, which is about 100 Times of norethindrone. Therefore, the dose can be halved compared with norgestrel, and adverse reactions will be reduced accordingly. Levonorgestrel mainly acts on the hypothalamus and pituitary gland, which significantly reduces or disappears the peaks of FSH and LH levels in the middle of menstruation. The ovaries do not ovulate and have obvious anti-estrogen activity. Its anti-estrogen activity is stronger than norethindrone 10 times(Note: Norethindrone is a synthetic progesterone preparation of estradiol, a synthetic 19-desmethyltestosterone derivative, which has weak estrogenic and anti-estrogenic activity, and has mild androgen Activity and protein assimilation, its androgenic activity is approximately equivalent to 1/6 of testosterone). LNG has almost no estrogenic activity. It can thicken cervical mucus and hinder sperm penetration. It shows strong progesterone activity for the transformation of the endometrium, which can make the endometrium thin, and the endometrial epithelial cells are low columnar, and the secretion function is poor, which is not conducive to the implantation of pregnant eggs. LNG also has a certain androgenic activity and protein assimilation, which can inhibit ovulation by oral or subcutaneous injection [3]. ③The levonorgestrel contained in the levonorgestrel intrauterine sustained-release system is an extremely effective progesterone, which mainly acts locally [4-6]. ④ What is the actual blood concentration of levonorgestrel released by the intrauterine release system of levonorgestrel? It has been reported in the literature that about 10% of levonorgestrel is released in the systemic circulation. Some patients may still have hormone-related complaints, such as breast tenderness, acne, mood changes, weight gain, hair loss, hirsutism or general swelling. Some patients will have functional ovarian cysts. These phenomena are more obvious in the first few months of use and will gradually decrease with the extension of use time. This is actually related to the patients’ extreme sensitivity to levonorgestrel [7]. ⑤The concentration of LNG in the blood circulation of women using LNG-IUS is very low and stable. Pharmacokinetic studies have shown that the plasma concentration reached by the LNG sustained-released by LNG-IUS in the uterine cavity is maintained at 0.4-0.6nmol/L (150-200pg/ml) through the intimal basal capillary network to reach the blood circulation. The blood concentration of commonly used oral contraceptives is low, and the concentration in the fallopian tube is also very low [8]. Another study reported that the median blood LNG concentration of women who used LNG-IUS within 7 years was 125-200ng/L [9]. ⑥The Levonorgestrel-releasing Intrauterine system often causes amenorrhea in patients. Isn’t menstruation after LNG-IUS a sign of ovarian function decline? Will the patient get older as a result? will not. A large number of studies have confirmed [10-12] that LNGIUS does not affect the patient’s ovarian function, ovarian cycle, and estrogen secretion. The amenorrhea caused by LNG-IUS is mainly caused by the local inhibition of LNG on the endometrium. This inhibition is caused by the local high level of LNG on the endometrial estrogen receptor down-regulation, so that the endometrium is against the endogenous Sexual and exogenous estrogen are not sensitive, and inhibit the intimal hyperplasia reaction, resulting in oligomenorrhea and even amenorrhea after LNG-IUS use. And this inhibition is reversible. After the birth control ring is removed, as long as the patient’s ovarian function is present, the normal menstrual cycle can still be restored. After the LNG-IUS is taken out, menstruation can be recovered, and the average recovery time is 23 days. Therefore, the ovaries of patients with LNG-IUS can still secrete E2 hormones normally, and will not cause the increase of FSH, and can have a normal ovulation cycle. ⑦So, what mechanism does the levonorgestrel intrauterine sustained-release system use to exert its high-efficiency contraceptive effect? It mainly includes three aspects: a. Continuous inhibition of the endometrium, which interferes with or is not conducive to the implantation of fertilized eggs; b. Increases the consistency of cervical mucus and inhibits the passage of sperm (the increase in the consistency of cervical mucus can effectively inhibit retrograde infection and reduce the pelvic cavity The occurrence of inflammatory diseases); c. Antifertilization: inhibit the activity and function of sperm in the uterus and fallopian tubes, and prevent fertilization [5,9].

Clinical Application of Levonorgestrel-Releasing Intrauterine System

What are the main clinical applications of Levonorgestrelreleasing Intrauterine system? In summary, the main points are as follows [13-24]: ①Long-acting reversible contraception (LARC), which has a contraceptive effect comparable to sterilization; ②Functional uterine bleeding and menorrhagia; ③Resistance to menstruation caused by uterine fibroids More therapeutic effects; ④Therapeutic effect on adenomyosis; ⑤Maintenance treatment after endometriosis; ⑥The effect of LNG-IUS in relieving dysmenorrhea; ⑦The protective effect of endometrium in HRT; ⑧Tamoxifen treatment after breast cancer surgery Endometrial protection; ⑨impact on endometrial hyperplasia and endometrial cancer.

The 2016 British Endometrial Hyperplasia Management Guidelines pointed out that for the hormone treatment of endometrial hyperplasia, the Levonorgestrel-releasing Intrauterine system is listed as the first choice. Progesterone therapy is prioritized to recommend the Levonorgestrel-releasing Intrauterine system, that is, Mirena (LNG-IUS× at least 6 months, preferably × 5 years for those without a childbirth plan), which can obtain a higher remission rate. According to the 2016 UK Endometrial Hyperplasia Management Guidelines and the 2017 China Endometrial Hyperplasia Diagnosis and Treatment Consensus [25-26], for the treatment of endometrial hyperplasia, whether it is the treatment of no dysplasia or atypical hyperplasia, LNG-IUS seems to have been Placed in a very important position, this is slightly different from the previous view (the dysplasia should be converted with high-efficiency progesterone before considering the placement of LNG-IUS maintenance therapy [27-29]). However, whether these new ideas can be widely and consistently adopted remains to be confirmed by the test of time and further research.

For More Open Access Journals in Iris Publishers Please Click on: https://irispublishers.com/

For More Information:
https://irispublishers.com/wjgwh/fulltext/an-overview-of-the-basic-knowledge-of-levonorgestrel-releasing-intrauterine-systeml.ID.000602.php